Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?

1.11K
67
3

Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?

Motley Fool2022-02-01

Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1.11K

Report

Comment（67）

BKT
·2022-02-01
Good. Pls like thanks.
Reply
Like
Report
Ignis
·2022-02-01
Can
Reply
3
Report
Wkmk
·2022-02-01
Like
Reply
3
Report
sheenayam
·2022-02-01
Like
Reply
3
Report
MrTig3r
·2022-02-01
power
Reply
3
Report
angelo0908
·2022-02-01
Goof
Reply
1
Report
Bspn
·2022-02-01
Ok
Reply
1
Report
YxZ
·2022-02-01
[Happy]
Reply
1
Report
zbhtet
·2022-02-01
Pls like
Reply
2
Report
chaicka
·2022-02-01
[Glance] I thought holdings on BMY has already been sold off/cash-out in late 2021?
Reply
3
Report
rayjs
·2022-02-01
Aaaa
Reply
5
Report
superduper
·2022-02-01
Buy
Reply
3
Report
WillsonToh
·2022-02-01
Just buy only
Reply
4
Report
lewisleeks
·2022-02-01
Great tiger year [Smile] [Smile]
Reply
4
Report
KeeBoonTong
·2022-02-01
Lalalala
Reply
3
Report
kenong62
·2022-02-01
Please likeThanks 👍
Reply
7
Report
LimLS
·2022-02-01
I prefer Apple from Buffet. Always a strong company with a super earning power. Always my choice when valuation is close to it's historical mean
Reply
6
Report
佛脚哥未必是狂澜哥
·2022-02-01
Please like!
Reply
6
Report
njkk
·2022-02-01
Pls like
Reply
5
Report
STSL
·2022-02-01
Ok
Reply
5
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2207226382?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-01 08:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2207226382","market":"us","top_or_hot":-1,"title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","media":"Motley Fool","content":"<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMY","symbol_name":"施贵宝","start_time":0,"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","article_id":"2207226382","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","pubTimestamp":1643674838,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMY":"施贵宝","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4007":"制药","BK4566":"资本集团","BK4176":"多领域控股","BK4532":"文艺复兴科技持仓","BK4099":"汽车制造商","BRK.B":"伯克希尔B","BK4559":"巴菲特持仓","GM":"通用汽车","BK4557":"大麻股","BRK.A":"伯克希尔","BK4561":"索罗斯持仓","BK4534":"瑞士信贷持仓"},"translate_title":"沃伦·巴菲特的3只最便宜的股票是不是在叫卖？","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1,"GM":1,"BMY":1,"BRK.B":0.9,"BRK.A":0.9},"content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9091081687,"gmtCreate":1643731043464,"gmtModify":1676533849794,"author":{"id":"3570853427202414","authorId":"3570853427202414","name":"BKT","avatar":"https://community-static.tradeup.com/news/15cb8e8f0a7c44ca01c83b3bfdddbd86","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570853427202414","authorIdStr":"3570853427202414"},"htmlText":"Good. Pls like thanks.","listText":"Good. Pls like thanks.","text":"Good. Pls like thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091081687","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093734270,"gmtCreate":1643704653450,"gmtModify":1676533846547,"author":{"id":"3574686466924712","authorId":"3574686466924712","name":"Ignis","avatar":"https://static.tigerbbs.com/543d1f3e8b4901fba226eb61e5713bc4","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":0,"idStr":"3574686466924712","authorIdStr":"3574686466924712"},"htmlText":"Can","listText":"Can","text":"Can","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093734270","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093731384,"gmtCreate":1643703550270,"gmtModify":1676533846424,"author":{"id":"4101985304496410","authorId":"4101985304496410","name":"Wkmk","avatar":"https://static.tigerbbs.com/b5afff3c91027e319e71557d19d8b21b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4101985304496410","authorIdStr":"4101985304496410"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093731384","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093797109,"gmtCreate":1643702354221,"gmtModify":1676533846327,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093797109","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093793510,"gmtCreate":1643700544398,"gmtModify":1676533846168,"author":{"id":"3584333947690568","authorId":"3584333947690568","name":"MrTig3r","avatar":"https://static.tigerbbs.com/b99cfe4b0a492018c40761a39a193aa8","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3584333947690568","authorIdStr":"3584333947690568"},"htmlText":"power","listText":"power","text":"power","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093793510","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093799489,"gmtCreate":1643700344942,"gmtModify":1676533846153,"author":{"id":"4097296316103040","authorId":"4097296316103040","name":"angelo0908","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4097296316103040","authorIdStr":"4097296316103040"},"htmlText":"Goof","listText":"Goof","text":"Goof","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093799489","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093790983,"gmtCreate":1643699815689,"gmtModify":1676533846107,"author":{"id":"3582502134655895","authorId":"3582502134655895","name":"Bspn","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3582502134655895","authorIdStr":"3582502134655895"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093790983","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093704808,"gmtCreate":1643699481731,"gmtModify":1676533846059,"author":{"id":"3581585073188396","authorId":"3581585073188396","name":"YxZ","avatar":"https://community-static.tradeup.com/news/a017789f7bf3b1d82aff6840186fc6ff","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581585073188396","authorIdStr":"3581585073188396"},"htmlText":"[Happy]&nbsp;","listText":"[Happy]&nbsp;","text":"[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093704808","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093705452,"gmtCreate":1643699404873,"gmtModify":1676533846051,"author":{"id":"4088495159199840","authorId":"4088495159199840","name":"zbhtet","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4088495159199840","authorIdStr":"4088495159199840"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093705452","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093700610,"gmtCreate":1643697070872,"gmtModify":1676533845827,"author":{"id":"4090019857770890","authorId":"4090019857770890","name":"chaicka","avatar":"https://static.tigerbbs.com/c0c291a2a7983f128cf68e5b01fedd73","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4090019857770890","authorIdStr":"4090019857770890"},"htmlText":"[Glance]&nbsp;I thought holdings on BMY has already been sold off/cash-out in late 2021?","listText":"[Glance]&nbsp;I thought holdings on BMY has already been sold off/cash-out in late 2021?","text":"[Glance] I thought holdings on BMY has already been sold off/cash-out in late 2021?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093700610","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093477938,"gmtCreate":1643696701613,"gmtModify":1676533845803,"author":{"id":"3582194391985550","authorId":"3582194391985550","name":"rayjs","avatar":"https://static.tigerbbs.com/c7c5a87eb80a4d23caa89490493c51fd","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582194391985550","authorIdStr":"3582194391985550"},"htmlText":"Aaaa","listText":"Aaaa","text":"Aaaa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093477938","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093474366,"gmtCreate":1643696340950,"gmtModify":1676533845772,"author":{"id":"3581550518409224","authorId":"3581550518409224","name":"superduper","avatar":"https://static.tigerbbs.com/04a121c70123b41a7011f9ec45096505","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3581550518409224","authorIdStr":"3581550518409224"},"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093474366","repostId":2207226382,"repostType":2,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093478454,"gmtCreate":1643695586745,"gmtModify":1676533845698,"author":{"id":"4105235879329900","authorId":"4105235879329900","name":"WillsonToh","avatar":"https://community-static.tradeup.com/news/bfa698a409feaf8767914264abdbae58","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":0,"idStr":"4105235879329900","authorIdStr":"4105235879329900"},"htmlText":"Just buy only&nbsp;","listText":"Just buy only&nbsp;","text":"Just buy only","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093478454","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093478193,"gmtCreate":1643695541626,"gmtModify":1676533845690,"author":{"id":"4089010444435920","authorId":"4089010444435920","name":"lewisleeks","avatar":"https://static.tigerbbs.com/d39cf835a09bdd21dce8a780b993940c","vip":1,"crmLevel":1,"crmLevelSwitch":1,"idStr":"4089010444435920","authorIdStr":"4089010444435920"},"htmlText":"Great tiger year&nbsp;[Smile]&nbsp;[Smile]&nbsp;","listText":"Great tiger year&nbsp;[Smile]&nbsp;[Smile]&nbsp;","text":"Great tiger year [Smile] [Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093478193","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093471502,"gmtCreate":1643695417938,"gmtModify":1676533845674,"author":{"id":"3578717603960999","authorId":"3578717603960999","name":"KeeBoonTong","avatar":"https://static.tigerbbs.com/815864515bc02d554ba00b04f5f46a1a","vip":1,"hat":"https://static.tigerbbs.com/6444b4970948c1077534c593eccd6d16","crmLevel":4,"crmLevelSwitch":1,"idStr":"3578717603960999","authorIdStr":"3578717603960999"},"htmlText":"Lalalala","listText":"Lalalala","text":"Lalalala","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093471502","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093454026,"gmtCreate":1643691411174,"gmtModify":1676533845198,"author":{"id":"3574928367638029","authorId":"3574928367638029","name":"kenong62","avatar":"https://static.tigerbbs.com/37fd00bd8cea11b8aa1aed6d9ddd9413","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3574928367638029","authorIdStr":"3574928367638029"},"htmlText":"Please likeThanks 👍","listText":"Please likeThanks 👍","text":"Please likeThanks 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093454026","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093452941,"gmtCreate":1643691094098,"gmtModify":1676533845170,"author":{"id":"3572923586954779","authorId":"3572923586954779","name":"LimLS","avatar":"https://static.tigerbbs.com/217b03b0c4808fb537070ba4e8f9d83f","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3572923586954779","authorIdStr":"3572923586954779"},"htmlText":"I prefer Apple from Buffet. Always a strong company with a super earning power. Always my choice when valuation is close to it's historical mean","listText":"I prefer Apple from Buffet. Always a strong company with a super earning power. Always my choice when valuation is close to it's historical mean","text":"I prefer Apple from Buffet. Always a strong company with a super earning power. Always my choice when valuation is close to it's historical mean","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093452941","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093451150,"gmtCreate":1643690609349,"gmtModify":1676533845096,"author":{"id":"3578006677235346","authorId":"3578006677235346","name":"佛脚哥未必是狂澜哥","avatar":"https://community-static.tradeup.com/news/620bde0c4f5c8600ef8992fa69528552","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3578006677235346","authorIdStr":"3578006677235346"},"htmlText":"Please like!","listText":"Please like!","text":"Please like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093451150","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093453395,"gmtCreate":1643690517760,"gmtModify":1676533845064,"author":{"id":"3575950181915531","authorId":"3575950181915531","name":"njkk","avatar":"https://static.tigerbbs.com/6382201e8e84ccd3f8e89b9a28e74607","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575950181915531","authorIdStr":"3575950181915531"},"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093453395","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093450596,"gmtCreate":1643690245018,"gmtModify":1676533845040,"author":{"id":"3586492916274801","authorId":"3586492916274801","name":"STSL","avatar":"https://static.tigerbbs.com/49e8aa4445808964ca4d2a2f3937956e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586492916274801","authorIdStr":"3586492916274801"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093450596","repostId":2207226382,"repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4557":"大麻股","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","GM":"通用汽车","BK4561":"索罗斯持仓","BK4176":"多领域控股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4007":"制药","BMY":"施贵宝","BK4099":"汽车制造商","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1108,"commentSize":67,"repostSize":0,"favoriteSize":3,"likeStatus":false,"favoriteStatus":false}}